Exclusive Summary

• Irbesartan, an established sartans antihypertensive, benefits from expired patents, a mature market, and a vast global hypertensive patient population.
• The product is FDA GMP certified and already launched in the US, providing international quality assurance and facilitating direct distribution partnerships in established markets.
• Irbesartan is listed on the WHO Essential Medicines List and recommended as a first-line treatment for hypertension by major guidelines, ensuring stable and continuous market demand.
• As a generic, the product offers a significant cost advantage over the originator, appealing to global healthcare systems focused on cost containment.
• Its successful launch in the US, though not a first-to-market generic, serves as a strong quality and regulatory endorsement to build trust in other international markets.